1 The relationship between mental health, sleep quality, and

2 the immunogenicity of COVID-19 vaccinations

- 3 Short title: Mental health, sleep, and COVID-19 vaccinations
- 4 Isabell Wagenhäuser^{1,2}; Julia Reusch^{1,2}; Alexander Gabel, PhD¹; Juliane Mees, MSc¹; Helmut
- 5 Nyawale, MD^{3,4}; Anna Frey, MD²; Thiên-Trí Lâm, MD⁴; Alexandra Schubert-Unkmeir, MD⁴;
- 6 Lars Dölken, MD⁵; Oliver Kurzai, MD^{4,6}; Stefan Frantz, MD²; Nils Petri, MD²; Manuel Krone,
- 7 MD, MScPH^{1,4}; Lukas B. Krone, MD, PhD^{7,8,9}
- 8 ¹ Infection Control and Antimicrobial Stewardship Unit, University Hospital Würzburg,
- 9 Würzburg, Germany
- 10 ² Department of Internal Medicine I, University Hospital Würzburg, Würzburg, Germany
- ³ Department of Microbiology and Immunology, Weill Bugando School of Medicine, Catholic
- 12 University of Health and Allied Sciences, Mwanza, Tanzania
- ⁴ Institute for Hygiene and Microbiology, Julius-Maximilians-Universität Würzburg, Würzburg,
- 14 Germany
- 15 ⁵ Institute for Virology and Immunobiology, Julius-Maximilians-Universität Würzburg,
- 16 Würzburg, Germany
- ⁶ Leibniz Institute for Natural Product Research and Infection Biology Hans-Knoell-Institute,
- 18 Jena, Germany
- ⁷ Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, UK
- ⁸ Sir Jules Thorn Sleep and Circadian Neuroscience Institute, University of Oxford, Oxford,
- 21 UK
- ⁹ University Hospital of Psychiatry and Psychotherapy, University of Bern, Bern, Switzerland NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

24 Corresponding author:

- 25 Lukas B. Krone
- 26 University Hospital of Psychiatry and Psychotherapy
- 27 Murtenstrasse 21, 3008 Bern, Switzerland
- 28 Phone: +44 (0) 7397 291184
- 29 E-mail: lukas.krone@dpag.ox.ac.uk
- 30
- 31 Word count: 3,828
- 32 Number of References: 46

33

35 Conflicts of Interest

- 36 Manuel Krone receives honoraria from GSK and Pfizer outside the submitted work. All other
- 37 authors declare no potential conflicts of interest.

- 39 Author contributions
- 40 All authors had unlimited access to all data. Isabell Wagenhäuser, Julia Reusch, Nils Petri,
- 41 Manuel Krone, and Lukas B. Krone take responsibility for the integrity of the data and the
- 42 accuracy of the data analysis.
- 43 Conception and design: Thiên-Trí Lâm, Anna Frey, Alexandra Schubert-Unkmeir, Lars Dölken,
- 44 Oliver Kurzai, Stefan Frantz, Nils Petri, Manuel Krone, Lukas B. Krone.
- 45 *Trial management*: Isabell Wagenhäuser, Julia Reusch, Juliane Mees, Nils Petri, Manuel
 46 Krone.
- 47 Laboratory analysis: Isabell Wagenhäuser, Julia Reusch, Juliane Mees, Helmut Nyawale.
- 48 Statistical analysis: Isabell Wagenhäuser, Alexander Gabel, Juliane Mees, Manuel Krone,
- 49 Lukas B. Krone.
- 50 *Obtained funding*: Oliver Kurzai, Manuel Krone, Lukas B. Krone.
- 51 *First draft of the manuscript*: Isabell Wagenhäuser, Lukas B. Krone.
- 52 The manuscript was reviewed and approved by all the authors.

53 Abstract

54 Sleep modulates the immune response and sleep loss can reduce the immunogenicity of 55 certain vaccinations. Vice versa immune responses impact sleep. We aimed to investigate the 56 influence of mental health and sleep quality on the immunogenicity of COVID-19 vaccinations 57 and, conversely, of COVID-19 vaccinations on sleep quality.

The prospective CoVacSer study monitored mental health, sleep quality, and Anti-SARS-CoV-2-Spike IgG titres in a cohort of 1,082 healthcare workers from the 29th of September 2021 to the 19th of December 2022. Questionnaires and blood samples were collected before, 14 days, and three months after the third COVID-19 vaccination. In 154 participants the assessments were also conducted before and 14 days after the fourth COVID-19 vaccination.

Healthcare workers with psychiatric disorders had slightly lower Anti-SARS-CoV-2-Spike IgG levels before the third COVID-19 vaccination. However, this effect was mediated by higher median age and body mass index in this subgroup. Antibody titres following the third and fourth COVID-19 vaccination ('booster vaccinations') were not significantly different between subgroups with and without psychiatric disorders. Sleep quality did not affect the humoral immunogenicity of the COVID-19 vaccinations. Moreover, the COVID-19 vaccinations did not impact self-reported sleep quality.

Our data suggests that in a working population neither mental health nor sleep quality relevantly impact the immunogenicity of COVID-19 vaccinations and that COVID-19 vaccinations are not a precipitating factor for insomnia. The findings from this large-scale real-life cohort study will inform clinical practice regarding the recommendation of COVID-19 booster vaccination for individuals with mental health and sleep problems.

77 Key words

- 78 COVID-19 vaccination, immune response, psychiatric disorders, system consolidation, sleep
- 79 function, sleep regulation

81 Introduction

The immunogenicity of vaccinations is modulated by a plethora of physiological and behavioural influences (Zimmermann & Curtis, 2019). A bidirectional relationship between sleep and immune function is well established (Besedovsky et al., 2019). Sleep can modulate the cellular and humoral response to vaccinations (Lange et al. 2011). Vice versa, vaccinations can impact sleep (Sharpley et al., 2016) and immune system activation might be involved in the pathophysiological hyperarousal of insomnia patients (Riemann et al., 2020; Riemann et al., 2010).

89 Previous work on the impact of sleep on immunogenicity of different vaccinations has found 90 that experimental sleep restriction and sleep deprivation as well as habitual short sleep impair 91 the humoral immune response following influenza, hepatitis A, and hepatitis B vaccinations 92 (Rayatdoost et al., 2022). The most extensive study monitored antibody levels for one year 93 over a course of three vaccinations against hepatitis A and showed that whole night of sleep 94 deprivation after each of the vaccinations significantly reduced antibody levels in the short and 95 long term (Lange et al., 2011), supporting previous findings of reduced hepatitis A antibody 96 levels four weeks after a single hepatitis A vaccination was followed by experimental sleep 97 deprivation (Lange et al., 2003). However, for other vaccines the effects of sleep deprivation 98 are less clear. Volunteers undergoing six days of bedtime restriction around a seasonal 99 influenza vaccination had only half of the antibody levels at 10 days post vaccination compared 100 to normally sleeping volunteers, but 3-4 weeks following the sleep restriction antibody levels 101 no longer differed between groups (Spiegel et al., 2002). Similarly, one night of sleep 102 deprivation following an influenza H1N1 vaccination impacted the antibody levels only in the 103 five-day follow up in males and while there was no difference to controls in females or males 104 at later time points (Benedict et al., 2012). The relationship between short sleep and reduced 105 vaccination response was corroborated by two studies investigating the effect of sleep habits 106 immunogenicity of hepatitis B (Prather et al., 2012) and a tetravalent influenza vaccination 107 (Prather et al., 2021). However, in both studies neither sleep efficiency nor sleep quality 108 mediated antibody levels. Similarly, sleep disruptions due to obstructive sleep apnoea did not affect antibody levels (Dopp et al., 2007). If sleep disorders impact vaccination immunogenicity also remains unclear following a study on influenza vaccination in insomnia patients (Taylor et al., 2017). This study found lower antibody levels in insomnia patients at baseline and after the vaccination as well as some indications from exploratory analyses that insomnia and the Pittsburgh Sleep Quality Index (PSQI) might mediate the vaccination response (Buysse et al., 1989). However, the main analysis showed no interaction effect between the time point (before vs. after vaccination) and the group (insomnia vs. controls).

116 The COVID-19 vaccination has become a key prevention tool in the ongoing COVID-19 117 pandemic (Benenson et al., 2021). It has been speculated that poor sleep quality may impair 118 the COVID-19 vaccination derived humoral immune response (Kow & Hasan, 2021; Zhu et al., 119 2021), particularly in individuals with psychiatric disorders (Mazereel et al., 2021). However, 120 data on the relationship between sleep and immunogenicity of COVID-19 vaccinations is still sparse. To our knowledge, currently the first has recently been conducted in a small cohort of 121 122 Greek healthcare workers (HCWs) (Athanasiou et al., 2023). Surprisingly, night shifts two days 123 before or one day after COVID-19 vaccination did not affect antibody levels. However, the 124 Athens Insomnia Scale (AIS) (Soldatos et al., 2000) and the PSQI predicted antibody levels 125 after the first and second vaccination (Athanasiou et al., 2023), yet to a smaller degree than 126 other established factors such as age and smoking. Considering that the study participants 127 were assessed during the peak of the COVID-19 pandemic and severely sleep deprived with 128 an average sleep duration of only six hours per night, it remains unclear if the effects were 129 mediated by sleep duration, sleep quality or other factors such as mental health.

Mental health, however, is another important aspect to consider in the vaccination response (Mazereel et al., 2021). Some mental health conditions, in particular major depressive disorder, can reduce vaccine efficacy (Xiao et al., 2022). Yet, the current evidence regarding the effect of psychiatric disorders on vaccine immunogenicity is heterogenous and data on the COVID-19 vaccination is missing (Mazereel et al., 2021; Xiao et al., 2022). Considering that the COVID-19 pandemic has now been ongoing for more than three years (Wu et al., 2020), and the novel mRNA-based vaccines (Baden et al., 2020; Polack et al., 2020) have been administered to

billions of individuals worldwide, it is surprising that the impact of sleep and mental health on
the COVID-19 vaccine immunogenicity and the impact of the vaccination on sleep have not
yet been studied in a large cohort.

140 We set out to use our large-scale real-life data of 1,082 HCWs undergoing their third and fourth 141 COVID-19 vaccination (first and second booster vaccination) to address this question. The 142 sample of HCWs is particularly relevant for vaccine recommendations as this population is, on 143 one hand, highly exposed to SARS-CoV-2 and needs the best possible vaccination protection 144 (Gross et al., 2021; Montgomery et al., 2021), but on the other hand, predisposed to poor sleep 145 and mental stress due to their daily work (Anderson et al., 2012; Chang et al., 2013; Wolkow 146 et al., 2015). We therefore tested in this sample if mental health and sleep quality affect the 147 immune response following COVID-19 vaccination and, vice versa, whether the COVID-19 148 vaccination affects sleep quality.

149

151 2 Methods

152 2.1 Study setting

153 This project was part of the CoVacSer cohort study which investigates prospectively the 154 SARS-CoV-2 immunity, guality of life, and ability to work in HCWs after COVID-19 vaccination 155 and/or SARS-CoV-2 infection. Inclusion criteria for study enrolment were: (i) age \geq 18 years, 156 (ii) written consent form, (iii) 14 days minimum interval after the first polymerase chain reaction 157 (PCR) confirmed SARS-CoV-2 infection and/or at least one dose of COVID-19 vaccination 158 independent of vaccination regime, (iv) employment in healthcare sector. Individuals that 159 received vaccines without European Medicines Agency (EMA) authorisation during the data 160 collection period were excluded from the data analysis according to the study 161 protocol.(European Medicines Agency (EMA), 2023)

- 162 2.2 Data collection
- 163 The data was collected between the 29th of September 2021 to the 19th of December 2022.
- 164 Analysis was performed based on the vaccination status:
- 165 (A) third mRNA-based COVID-19 vaccination (first booster dose)
- 166 (B) fourth mRNA-based COVID-19 vaccination (second booster dose)
- 167 The following COVID-19 vaccines were used:
- i. monovalent BNT162b2mRNA (Comirnaty, BioNTech/Pfizer, Mainz/Germany, New
 York/USA; full dose 30µg mRNA)
- ii. mRNA-1273 (Spikevax, Moderna, Cambridge/USA; half dose 50g mRNA as booster
 dose following the recommendations of the German constant vaccination committee
- 172 (STIKO) (Robert Koch-Institut (RKI), 2021)
- iii. bivalent BNT162b2 mRNA Original/Omicron BA.1 (Comirnaty Original/Omicron BA.1,
 BioNTech/Pfizer, Mainz/Germany, New York/USA)
- 175 iv. bivalent BNT162b2 mRNA Original/Omicron BA.4-5 (Comirnaty Original/Omicron
- 176 BA.4-5, BioNTech/Pfizer, Mainz/Germany, New York/USA)

177	The study participants submitted the CoVacSer study survey with a corresponding serum
178	blood sample at each participation date, which were defined in the study protocol:
179	1. pre-vaccination baseline assessment before the respective COVID-19 booster
180	vaccine administration
181	2. assessment 14 to 30 days after each booster vaccination, referred to as 14-days
182	post-vaccination participation.
183	3. follow-up assessment 60 to 120 days after booster vaccination, referred to as 3-month
184	follow-up.
185	Because most participants who received a fourth vaccination dose were vaccinated less than
186	three months before the end date of the data collection period, the 3-month follow-up data was
187	only analysed for the third COVID-19 vaccination.
188	The CoVacSer study survey includes socio-demographic aspects and individual risk factors,
189	containing the World Health Organisation Quality of Life (WHOQOL-BREF) questionnaire as
190	well as the Work Ability Index (WAI) (Gholami et al., 2013; Skevington, 1999; van den Berg et
191	al., 2009).
192	The ability to enjoy life, the ability to concentrate, energy for everyday life, and acceptance of
193	one's own appearance were asked in the categories "not at all", "a little", "average", "quite" and
194	"extremely". Satisfaction with the ability to cope with everyday life, self-satisfaction, satisfaction
195	with sexual life, as well as the quality of sleep were queried in the categories "very dissatisfied",
196	"dissatisfied", "neither satisfied nor dissatisfied", "satisfied", and "very satisfied". The frequency
197	of occurrence of negative feelings in the frequency intervals "never", "not often", "occasionally",
198	"often", and "always". Participants werer instructed to rate all items for 14-days period prior to
199	the respective assessment date.
200	For the analysis on the impact of mental health on vaccine immunogenicity, study participants

without psychiatric disorders were compared to those who indicated to have a psychiatric disorder. To determine whether or not participants had a psychiatric disorder, the questionnaire entry 14 days after the third or fourth vaccination was used. For the analysis of the effect of

sleep quality on the humoral immunogenicity of the COVID-19 vaccination, the sleep quality
 reported at the 14-days assessment after vaccination was used, as this refers to the time span
 immediately following the vaccination.

207 Only blood samples with a signed written consent form and a completed linked questionnaire 208 were considered. REDCap (Research Electronic Data Capture, projectredcap.org) was used 209 as technological platform for the questionnaire recording (Harris et al., 2019; Harris et al., 2009). In the context of pseudonymisation, blood samples were assigned to the study survey 211 based on date of birth and dates of COVID-19 vaccination.

212 Most HCWs were recruited from a single tertiary hospital in Germany, the University Hospital 213 Würzburg, along with some HCWs from surrounding hospitals and medical surgeries.

214 2.3 SARS-CoV-2 IgG ELISA

215 The measurement of Anti-SARS-CoV-2-Spike IgG levels was performed using the SERION 216 ELISA agile SARS-CoV-2 IgG (SERION diagnostics, Würzburg, Germany) as an enzyme 217 linked immunoassay. Detected extinction values were converted to Serion IgG units per ml 218 (U/ml) as producer specific units in use of the software easyANALYSE (SERION diagnostics). 219 Consequently, the internationally established unit Binding Antibody Units per ml (BAU/ml) were 220 calculated using the factor 2.1 in accordance with manufacturer's information. For the 221 measurement of Anti-SARS-CoV-2-Spike-IgG levels beyond the maximum limit of 250 U/ml 222 (>525 BAU/mL), a dilution series containing dilution factors both 10 and 100 was conducted 223 consistent with previous studies (Krone et al., 2021; Perkmann et al., 2021).

224 2.4 Ethical approval

The study protocol was approved by the Ethics committee of the University of Würzburg in accordance with the Declaration of Helsinki (file no. 79/21).

227 2.5 Statistics

Data analysis was performed using GraphPad Prism 9.5.1 (GraphPad Software, San Diego,
CA, USA). For categorical variables the statistical significance levels were calculated using


230 Fisher's exact tests (gender composition of the study cohort in total and separated by mental 231 health status). For Anti-SARS-CoV-2-Spike IgG levels separated by psychiatric disorder status 232 the statistical significance levels were calculated using the Mann-Whitney U test. The 233 correlation of sleep quality and Anti-SARS-CoV-2-lgG levels was performed using a 234 Spearman-Rank correlation. A multiple regression model was used to evaluate the effect of 235 gender, age, BMI, smoking, SARS-CoV-2 convalescence, number of individuals living within 236 the same household, and days since the last COVID-19 immunising event at the baseline study 237 participation on Anti-Spike-SARS-CoV-2 IgG levels. The two-tailed significance level α was set 238 to 0.05.

239 3 Results

240 3.1 Participant recruitment and characterisation of the study population

From 29th of September 2021 to the 19th of December 2022, 1,158 CoVacSer study participants 241 242 submitted a serum blood sample along with the study guestionnaire 14 to 30 days after their 243 third COVID-19 vaccination. All individuals met the inclusion criteria. 76 participants were excluded because they had not participated in the study prior to the third vaccination, so the 244 245 third COVID-19 vaccination cohort consisted of 1,082 HCWs. Of the 155 HCWs who 246 participated 14 to 30 days after the fourth COVID-19 vaccination, one HCW was excluded due 247 to missing baseline participation prior to the fourth vaccination. 154 HCWs could be eventually 248 included for the cohort of the fourth COVID-19 vaccination (Figure 1).

For the third and fourth vaccination, assessments before and 14 days after the COVID-19 vaccination were conducted in all participants that received the respective vaccination. The 3-month follow-up after the third vaccination could be conducted in 785 (72.6%) individuals.



- 253 Figure 1: Recruitment of study participants
- A) Third COVID-19 vaccination. B) Fourth COVID-19 vaccination.

255

In the cohort of the **third COVID-19** vaccination (n=1,082 individuals), 86.0% (921) participants reported no, 14.0% (161) reported at least one psychiatric disorder. Separated by underlying psychiatric disorder, there was no significant difference in terms of gender composition, yet a clear trend towards a higher prevalence of psychiatric disorders in women (p=0.051, Fisher's 260 exact test, Table 1). HCWs with psychiatric disorders were on average older and had a higher 261 body weight (both p<0.001, Mann-Whitney U test, Table 1) compared to those without 262 psychiatric disorders, in line with the high comorbidity rates between obesity and mental health 263 disorders (Avila et al., 2015). They also lived with fewer people in the same household (p=0.02, 264 Mann-Whitney U test. We found no significant difference in the proportion of smokers among 265 individuals with or without psychiatric disorders (p=0.40, Mann-Whitney U test; Table 1). In 266 addition, the questionnaire assessment showed that participants with psychiatric disorders are 267 less able to enjoy their lives, less able to concentrate, have less energy for daily life, lower 268 self-acceptance of their appearance, an impaired ability to cope with everyday life, less 269 self-satisfaction, lower satisfaction with their sexual life, and have more often negative feelings 270 (all p<0.001, Mann-Whitney U test, Supplementary table 1).

study participants threefold COVID-19 vaccinated								
		mentally healthy (n=921)		underlying psychiatric disorder (n=161)		total (N=1,082)		р
		absolute	relative	absolute	relative	absolute number	relative number	
aondor	female	761	82.6%	143	88.8%	904	83.5%	0.051
gender	male	160	17.4%	18	11.2%	178	16.5%	
age [year	s]	41 (31- 52)		49 (37-58)		42 (31-54)		p<0.001
BMI [kg/m²]		23.7 (21.5- 26.6)		25.5 (22.0- 30.8)		23.8 (21.6- 27.2)		p<0.001
smoking individuals		323	35.1%	62	38.5%	385	35.6%	0.40
first post-vaccination participation: interval since third COVID-19 vaccination [days]		17 (15- 20)		17 (15-21)		17 (15-20)		0.47
interval of the prior COVID-19 immunsing event to the baseline participation [days]		236 (203- 266)		236 (207- 261)		236 (203- 265)		0.75
number of SARS-CoV-2 convalescent individuals		30	3.3.%	14	8.7%	44	4.1%	0.0013
household members [absolute number]		2 (2-3)		3 (1-3)		2 (2-3)		0.02

Table 1: Characterisation of the subgroups without and with psychiatric disorders undergoing a thirdCOVID-19 vaccination.

Age, BMI, the interval since the last COVID-19 vaccination, intermission between the pre- and the initial post-vaccination participation as well as the number of household members are reported as medians with interquartile ranges in brackets. For each sub-cohort absolute numbers in the left, relative share in the right column. BMI: body mass index.

278

279 In the cohort of the fourth COVID-19 vaccination (n=154 individuals), 87.7% (135) 280 participants reported no psychiatric disorder, 14.1% (19) HCWs reported at least one. In this 281 much smaller cohort, we found no significant difference in any of the demographic items. 282 However, again, individuals with psychiatric disorders tended to have a higher BMI (p=0.06, 283 Mann-Whitney U-test, Table 2). Consistent with their mental health status, participants with 284 psychiatric disorders indicated that they are less able to enjoy their lives, less able to 285 concentrate, have less energy for daily life, lower self-acceptance of their appearance, an 286 impaired ability to cope with everyday life, less self-satisfaction, and have more often negative 287 feelings (all p<0.001, Mann-Whitney U test, Supplementary Table 2) as well as reduced 288 satisfaction with their sexual life (p=0.0149, Mann-Whitney U test; Supplementary Table 2).

study participants fourfold COVID-19 vaccinated								
		mentally healthy (n=135)		underlying psychiatric disorder (n=19)		total (N=154)		р
		absolute	relative	absolute	relative	absolute	relative	
aandar	female	110	81.5%	17	89.5%	127	82.4%	0.53
gender	male	25	18.5%	2	10.5%	27	17.5%	
age [ye	age [years]			53 (45-59)		51 (37-58)		0.36
BMI [kg/m²]		24.2 (21.6- 28.0)		27.9 (21.5- 33.1)		24.4 (21.6- 28.3)		0.06
smoking indviduals		50	37.0%	5	26.3%	55	35.7	0.45
first post-vaccination participation: interval since fourth COVID-19 vaccination [days]		20 (17- 22)		17 (15-25)		20 (17-22)		0.20

interval of the prior COVID- 19 immunsing event to the baseline participation [days]	181 (116- 193)		169 (96-185)		180 (112- 191)		0.20
number of SARS-CoV-2 convalescent individuals	54	40.0%	4	21.1%	58	37.7	0.13
household members [absolute number]	2 (2-3)		2 (1-3)		2 (2-3)		0.32

Table 2: Characterisation of the subgroups without and with psychiatric disorders undergoing a

291 fourth COVID-19 vaccination

Age, BMI, the interval since the last COVID-19 vaccination, intermission between the pre- and the initial post-vaccination participation as well as the number of household members are reported as medians with interquartile ranges in brackets. For each sub-cohort absolute numbers in the left, relative share in the right column. BMI: body mass index.

296

3.2 Influence of mental health on post-vaccination Anti-SARS-CoV-2 spike IgG levels

To address the question of whether mental health impacts the Anti-SARS-CoV-2 spike IgG levels following COVID-19 vaccinations, we compared those study participants that reported no psychiatric disorder with those that indicated a psychiatric disorder.

301 In the third COVID-19 vaccination cohort, the median Anti-SARS-CoV-2-Spike IgG levels at 302 baseline before the third vaccination were 149 (IQR:80 -259) BAU/ml for participants without 303 and 119 (IQR:70-228) BAU/ml for participants with a psychiatric disorder. Hence, at baseline 304 before the third vaccination, Anti-SARS-CoV-2-Spike IgG levels were significantly lower 305 among HCWs with underlying psychiatric disorder (p=0.02, Mann-Whitney U test), while there 306 was no significant difference in Anti-SARS-CoV-2-Spike IgG levels at the time points 14-days 307 (p=0.20, Mann-Whitney U test) and 3-month (p=0.56, Mann-Whitney U test) after the third COVID-19 vaccination (Figure 2A). To investigate potential mediators for the significant 308 309 difference in Anti-SARS-CoV-2-Spike IgG levels between participants without and with 310 psychiatric disorders at baseline before the third COVID-19 vaccination, we performed an 311 explorative analysis using a multiple linear regression analysis. Age (p=0.03), SARS-CoV-2 312 infection convalescence (p<0.0001), and the interval between the last COVID-19 immunising 313 event (defined as latest administration of a COVID-19 vaccine or SARS-CoV-2 infection;

314 p<0.0001) significantly affected the Anti-SARS-CoV-2-Spike IgG levels, with higher age, 315 absence of previous infection, and longer intervals to the last immunising event predicting 316 lower antibody titres. Importantly, an underlying psychiatric disorder did not significantly 317 influence the humoral immune response (p=0.69).

- 318 In the **fourth COVID-19 vaccination** cohort, there was no significant difference in antibody 319 titres at baseline (p=0.59, Mann-Whitney U test) or 14 days after vaccination (p=0.48,
- 320 Mann-Whitney U test) between participants without and with psychiatric disorders (*Figure 2B*).







Figure 2: Anti-SARS-CoV-2-Spike IgG levels following COVID-19 booster vaccinations stratified by
 mental health status.

- **A)** Anti-SARS-CoV-2-Spike IgG levels among HCWs before (pre-vaccination) and after (14-days and
- 325 3-month follow up) the third COVID-19 vaccination. B) Anti-SARS-CoV-2-Spike IgG levels among HCWs
- 326 before (pre-vaccination) and after (14-days) the fourth COVID-19 vaccination.
- 327 Anti-SARS-CoV-2-Spike IgG logarithmically scaled. BAU/ml: binding antibody units per millilitre.
- 328 Medians are indicated as horizontal bold line, quartiles as dotted lines.
- 329 *: p < 0.05
- 330
- 331 3.3 Influence of sleep quality on post-vaccination Anti-SARS-CoV-2 spike IgG levels

332 We investigated the effect of sleep quality on Anti-SARS-CoV-2 spike IgG levels by comparing

- the antibody levels stratified by self-reported sleep quality.
- 334 In the third vaccination cohort, sleep quality and Anti-SARS-CoV-2-Spike IgG levels neither
- correlated pre-vaccination (p=0.93, r=0.002, Spearman correlation), 14-days (p=0.23, r=0.04,
- 336 Spearman correlation) nor 3-month post-vaccination (p=0.73, r=-0.012, Spearman correlation,
- 337 *Figure 3A*). In the fourth COVID-19 vaccination cohort, there was also no correlation between
- 338 sleep and Anti-SARS-CoV-2-Spike IgG levels pre-vaccination (p=0.11, r=-0.13, Spearman
- 339 correlation) nor 14-days post-vaccination (p=0.44, r=-0.06, Spearman correlation, *Figure 3B*).



340


341 Figure 3: Anti-SARS-CoV-2-Spike IgG levels following COVID-19 booster vaccinations stratified by342 sleep quality.

- **343** A) Anti-SARS-CoV-2-Spike IgG levels among HCWs before (pre-vaccination) and after (14-days and
- 344 3-month follow up) the third COVID-19 vaccination. B) Anti-SARS-CoV-2-Spike IgG levels among HCWs
- before (pre-vaccination) and after (14-days) the fourth COVID-19 vaccination. Sleep quality is stratified
- in five categories (very dissatisfied to very satisfied). Anti-SARS-CoV-2-Spike IgG logarithmically scaled.
- 347 BAU/ml: binding antibody units per millilitre.
- 348 Medians are indicated as horizontal bold line, quartiles as dotted lines.

350 3.4 Effect of COVID-19 vaccination on sleep quality

In order to assess whether the COVID-19 booster vaccinations affected sleep quality, we investigated the change of sleep quality across the time points before and after the third and fourth COVID-19 vaccination.

In the **third vaccination** cohort, there was no significant change in sleep quality following the vaccination (p=0.28 comparing the pre-vaccination sleep quality to the 14-days and p=0.59 to the 3-month post-vaccination assessment, p=0.63 comparing both post-vaccination participations; Mann-Whitney U test, (*Figure 4A*). Similarly, in the **fourth vaccination** cohort, there was no change in sleep quality in the 14 days following the vaccination (p=0.56, Mann-Whitney U test, *Figure 4B*).



361 Figure 4: Sleep quality before and after COVID-19 booster vaccinations

- 362 A) Sleep quality among HCWs before (pre-vaccination) and after (14-days and 3-month follow up) the
- 363 third COVID-19 vaccination (left: absolute numbers, right: relative share). B) Sleep quality among
- 364 HCWs before (pre-vaccination) and after (14-days) the fourth COVID-19 vaccination. Sleep quality is
- 365 stratified in five categories (very dissatisfied to very satisfied).

366 4 Discussion

367 Mental health, sleep, and immune function are interlinked, and it is of great clinical relevance 368 to clarify if individuals with psychiatric conditions or poor sleepers are at risk of an insufficient 369 response to COVID-19 booster vaccinations or if booster vaccinations might deteriorate sleep 370 guality. To our knowledge, this is the first study investigating the relationship between mental 371 health, sleep, and immunogenicity of COVID-19 booster vaccinations. In our large sample of 372 1,082 individuals, no effect of psychiatric disorders or sleep quality on the immunogenicity of 373 COVID-19 booster vaccinations and no effect of the booster vaccinations on sleep quality could 374 be obtained.

375 Participants with psychiatric disorders had slightly but significantly lower antibody titres before 376 the third COVID-19 booster vaccination compared to those without psychiatric disorders. 377 However, HCWs with a psychiatric disorder were significantly older and had a higher BMI. 378 Based on our regression analysis, the baseline differences in the Anti-SARS-CoV-2-Spike IgG 379 levels can be explained by these two moderators and not by the presence of psychiatric 380 disorders. At no other time point, Anti-SARS-CoV-2-Spike IgG levels differed between 381 individuals with and without psychiatric conditions. This is an important finding, as it suggests 382 that psychiatric conditions do not constitute a risk factor for an insufficient protection from 383 COVID-19 following booster vaccinations.

384 Our null finding on the relationship between sleep quality and vaccine immunogenicity is in line 385 with previous work that found an impact of sleep duration, but not of sleep quality or sleep 386 efficiency on the post-vaccination humoral immune response for hepatitis B and influenza 387 vaccinations (Prather et al., 2012; Prather et al., 2021) as well as with the finding that sleep 388 disruptions resulting from sleep apnoea do not affect antibody titres following an influenza 389 vaccination (Dopp et al., 2007). The difference between the clear effect of sleep restriction and 390 sleep deprivation on vaccine immunogenicity (Dopp et al., 2007), at least in the short term 391 (Benedict et al., 2012; Spiegel et al., 2002) and the absence of an impact of sleep quality or

sleep efficacy might be explained by the large discrepancy between subjective and objectivesleep variables, even in good sleepers (Benz et al., 2022).

Our null finding on the impact of the COVID-19 vaccinations on sleep quality provides another
important result as it shows that in our large dataset there is no indication that COVID-19
vaccinations might be a precipitating factor for insomnia.

397 Our study has some important limitations. This large and representative example of HCWs 398 represents a rather young and overall healthy population with only around 20% of participants 399 reporting dissatisfaction with their sleep, while in the adult population dissatisfactory sleep is 400 generally more common with more than 40% reporting some insomnia symptoms before the 401 COVID-19 pandemic and more than 50% of the population during the pandemic in 2020 (Morin 402 et al., 2021). The insomnia prevalence of 36% and the short sleep duration of only six hours 403 in the first study investigating the association of sleep variables and the immunogenicity of 404 COVID-19 vaccines might explain why the authors found a significant impact of the AIS and 405 PSQI scores on antibody levels at some time points after adjustment for potential confounders 406 (Athanasiou et al., 2023). It must be considered that both clinical scores include an item on 407 sleep duration (Buysse et al., 1989). Another important limitation of our study is that the cohort 408 is predominantly female. This is due to the recruitment of HCWs, which are mostly female in 409 the German healthcare system (Gesundheitsberichterstattung des Bundes, 2021). It should 410 further be mentioned as a limitation that for the fourth COVID-19 vaccination, data could only 411 be collected for the time of analysis 14 days after the vaccine administration, since most 412 follow-ups at 3 months post-vaccination and beyond have not yet been collected at the end of 413 the data collection period for this manuscript in December 2022. The cohort for the fourth 414 vaccination is also considerably smaller, as many individuals participating in the study for the 415 third vaccination were not eligible for a second booster following the COVID-19 vaccination 416 recommendations for HCWs of the German Standing Committee on Vaccination 417 (STIKO)(Robert Koch-Institut (RKI), 2021). This is due to the fact that a relatively large 418 proportion of the enrolled HCWs became infected with SARS-CoV-2 between the 3- and 419 6-month follow-up preventing an analysis of vaccine-induced increase of antibody titres. The

420 majority of subjects received the third COVID-19 vaccination in autumn 2021. In the context of 421 the high SARS-CoV-2 incidence phase, predominantly driven by the SARS-CoV-2 Omicron 422 virus variant of concern in early 2022, a large proportion suffered a breakthrough infection 423 (Bayerisches Landesamt für Gesundheit und Lebensmittelsicherheit, 2023). Regarding the 424 study design, it should be highlighted that sleep quality was only recorded retrospectively for 425 a 14-days time interval and based on the sleep quality item of the World Health Organisation 426 Quality of Life (WHOQOL-BREF) questionnaire (Gholami et al., 2013) and not on a day-by-day 427 self-report assessment with sleep diaries or an objective assessment with actigraphy or 428 polysomnography. It should also be noted that due to data protection regulations, the study 429 participants were not asked for a their specific psychiatric diagnosis and therefore it is not 430 possible to investigate the impact of mood disorders on vaccine immunogenicity that has 431 previously been found (Xiao et al., 2022).

432 Because of these limitations, mostly due to the real-life assessment in this large cohort study, 433 our data does not exclude the possibility that severely disturbed sleep, insomnia, or specific 434 mental health conditions might impact the immunogenicity of COVID-19 booster vaccinations. 435 However, our results suggest that low sleep quality or mental health conditions in general have 436 no relevant impact on antibody titres following COVID-19 booster vaccinations, especially 437 compared to established mediators of COVID-19 vaccine immunogenicity, specifically age, 438 smoking, and interval to the last immunising event (Reusch et al., 2022). While insomnia 439 patients generally underestimate their sleep (Benz et al., 2022), polysomnographic 440 measurements provide evidence for an objective reduction of sleep time in insomnia cohorts 441 (Baglioni et al., 2014). Only studies including objective and subjective sleep measurements 442 that are currently under way will be able to disentangle the impact of sleep quality and sleep 443 duration on COVID-19 vaccinations (Lammers-van der Holst et al., 2022).

We interpret our data as a null finding suggesting that sleep quality and mental health status do not require adjustments of vaccination schemes. Expert advice had been given that shift workers should avoid vaccinations on shift days and hospital inpatients should consider rescheduling their vaccinations due to the sleep disruptions associated with hospitalisation

(Zhu et al., 2021). However, the first and only previous study investigating the effects of sleep on antibody levels following COVID-19 vaccinations found no correlation between the duration of sleep two days prior and one day after the vaccination with antibody levels (Athanasiou et al., 2023). In light of this and our data, and because COVID-19 vaccinations represent an essential disease prevention measure (Benenson et al., 2021), COVID-19 vaccines should be applied in a timely manner.

Given the relevant impact of sleep on immune function and the hesitancy of COVID-19 booster vaccination in large segments of the population, especially among psychiatric patients, our large cohort study provides important evidence for recommending COVID-19 booster vaccination in individuals with psychiatric disorders and sleep problems.

458 In conclusion, our large-scale real-world study on 1,082 individuals finds no effect of mental 459 health and sleep quality on the immunogenicity of COVID-19 vaccinations and no change in 460 sleep quality following vaccinations. Because this study was conducted in a rather healthy and 461 young working population, it does not contradict previous experiments, demonstrating an 462 impact of experimental sleep deprivation or sleep restriction, and a potential influence of 463 insomnia disorder, on vaccination immunogenicity. However, our data suggests that sleep 464 guality does not have a major impact on Anti-SARS-CoV-2-Spike IgG levels following the 465 COVID-19 vaccination, especially compared to other established mediators of the vaccination 466 response such as age, body weight and time to the last immunising event. Importantly, our 467 data also indicates that COVID-19 vaccinations are not a precipitating factor for insomnia. 468 While the role of sleep in the effectiveness of vaccinations should be investigated in greater detail, our findings can be interpreted as reassuring evidence against a major impact of mental 469 470 health and sleep quality on the immunogenicity of COVID-19 vaccines or of the vaccine 471 administration on sleep quality.

472 Acknowledgements

We thank the staff of the serological diagnostic laboratory for making their laboratory availableand especially for their advisory help.

We explicitly thank Professor Ulrich Vogel, Infection Control and Antimicrobial Stewardship Unit, University Hospital Würzburg, Germany, for conception and design as well as funding support. He played a major role regarding the CoVacSer study but could not approve the final manuscript version as he died on the 4th of October 2022. We miss him as an enthusiastic college and friend who showed a great dedication to his work, family, and friends.

480 Funding

This study was funded by the Federal Ministry for Education and Science (BMBF) through a grant provided to the University Hospital of Würzburg by the Network University Medicine on COVID-19 (B-FAST, grant-No 01KX2021) as well as by the Free State of Bavaria with COVIDresearch funds provided to the University of Würzburg, Germany. Nils Petri is supported by the German Research Foundation (DFG) funded scholarship UNION CVD. Lukas B. Krone is supported by the Wellcome Trust (grant-No 203971/Z/16/Z) and Hertford College, Oxford, UK.

487 Role of funding source

This study was initiated by the investigators. The sponsoring institutions had no function in study design, data collection, analysis, and interpretation of data as well as in the writing of the manuscript. All authors had unlimited access to all data. Isabell Wagenhäuser, Julia Reusch, Nils Petri, Manuel Krone, and Lukas B. Krone had the final responsibility for the decision to submit for publication.

493 Data sharing statement

Additional data that underlie the results reported in this article, after de-identification (text, tables, figures, and appendices) as well as the study protocol, statistical analysis plan, and analytic code is made available to researchers who provide a methodologically sound proposal to achieve aims in the approved proposal on request to the corresponding author.

498 References


499 Anderson, C., Sullivan, J. P., Flynn-Evans, E. E., Cade, B. E., Czeisler, C. A., & 500 Lockley, S. W. (2012). Deterioration of Neurobehavioral Performance in 501 Resident Physicians During Repeated Exposure to Extended Duration Work 502 Shifts. Sleep, 35(8), 1137-1146. https://doi.org/10.5665/sleep.2004 Athanasiou, N., Baou, K., Papandreou, E., Varsou, G., Amfilochiou, A., Kontou, E., 503 504 Pataka, A., Porpodis, K., Tsiouprou, I., Kaimakamis, E., Kotoulas, S.-C., 505 Katsibourlia, E., Alexopoulou, C., Bouloukaki, I., Panagiotarakou, M., Dermitzaki, A., Charokopos, N., Pagdatoglou, K., Lamprou, K., Pouriki, S., 506 Chatzivasiloglou, F., Nouvaki, Z., Tsirogianni, A., Kalomenidis, I., Katsaounou, 507 508 P., & Vagiakis, E. (2023). Association of sleep duration and quality with 509 immunological response after vaccination against severe acute respiratory syndrome coronavirus-2 infection. Journal of Sleep Research, 32(1), e13656. 510 511 https://doi.org/https://doi.org/10.1111/jsr.13656 512 Avila, C., Holloway, A. C., Hahn, M. K., Morrison, K. M., Restivo, M., Anglin, R., & 513 Taylor, V. H. (2015). An Overview of Links Between Obesity and Mental 514 Health. Current Obesity Reports, 4(3), 303-310. 515 https://doi.org/10.1007/s13679-015-0164-9 516 Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., 517 Spector, S. A., Rouphael, N., Creech, C. B., McGettigan, J., Khetan, S., 518 Segall, N., Solis, J., Brosz, A., Fierro, C., Schwartz, H., Neuzil, K., Corey, L., Gilbert, P., Janes, H., Follmann, D., Marovich, M., Mascola, J., Polakowski, L., 519 520 Ledgerwood, J., Graham, B. S., Bennett, H., Pajon, R., Knightly, C., Leav, B., 521 Deng, W., Zhou, H., Han, S., Ivarsson, M., Miller, J., & Zaks, T. (2020). 522 Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. New England 523 Journal of Medicine, 384(5), 403-416. 524 https://doi.org/10.1056/NEJMoa2035389 525 Baglioni, C., Regen, W., Teghen, A., Spiegelhalder, K., Feige, B., Nissen, C., & Riemann, D. (2014). Sleep changes in the disorder of insomnia: a meta-526 analysis of polysomnographic studies. Sleep Med Rev, 18(3), 195-213. 527 528 https://doi.org/10.1016/j.smrv.2013.04.001 Bayerisches Landesamt für Gesundheit und Lebensmittelsicherheit. (2023). 529 530 Übersicht der Fallzahlen von Coronavirusinfektionen in Bayern, 531 https://www.lgl.bayern.de/gesundheit/infektionsschutz/infektionskrankheiten a 532 z/coronavirus/karte coronavirus/ (Accessed 26 February 2023). Benedict, C., Brytting, M., Markström, A., Broman, J.-E., & Schlöth, H. B. (2012). 533 534 Acute sleep deprivation has no lasting effects on the human antibody titer 535 response following a novel influenza A H1N1 virus vaccination. BMC 536 Immunology, 13(1), 1. https://doi.org/10.1186/1471-2172-13-1 537 Benenson, S., Oster, Y., Cohen, M. J., & Nir-Paz, R. (2021). BNT162b2 mRNA 538 Covid-19 Vaccine Effectiveness among Health Care Workers. New England 539 Journal of Medicine, 384(18), 1775-1777. 540 https://doi.org/10.1056/NEJMc2101951 Benz, F., Riemann, D., Domschke, K., Spiegelhalder, K., Johann, A. F., Marshall, N. 541 S., & Feige, B. (2022). How many hours do you sleep? A comparison of 542 543 subjective and objective sleep duration measures in a sample of insomnia 544 patients and good sleepers. Journal of Sleep Research, n/a(n/a), e13802. 545 https://doi.org/https://doi.org/10.1111/jsr.13802


Besedovsky, L., Lange, T., & Haack, M. (2019). The Sleep-Immune Crosstalk in 546 Health and Disease. Physiological Reviews, 99(3), 1325-1380. 547 548 https://doi.org/10.1152/physrev.00010.2018 549 Buysse, D. J., Reynolds, C. F., 3rd, Monk, T. H., Berman, S. R., & Kupfer, D. J. 550 (1989). The Pittsburgh Sleep Quality Index: a new instrument for psychiatric 551 practice and research. Psychiatry Res, 28(2), 193-213. 552 https://doi.org/10.1016/0165-1781(89)90047-4 Chang, Y.-S., Chen, H.-L., Hsu, C.-Y., Su, S.-F., Liu, C.-K., & Hsu, C. (2013). Nurses 553 554 working on fast rotating shifts overestimate cognitive function and the capacity 555 of maintaining wakefulness during the daytime after a rotating shift. Sleep 556 Medicine, 14(7), 605-613. 557 https://doi.org/https://doi.org/10.1016/j.sleep.2013.03.011 558 Dopp, J. M., Wiegert, N. A., Moran, J. J., Muller, D., Weber, S., & Hayney, M. S. (2007). Humoral Immune Responses to Influenza Vaccination in Patients with 559 Obstructive Sleep Apnea. Pharmacotherapy: The Journal of Human 560 561 Pharmacology and Drug Therapy, 27(11), 1483-1489. https://doi.org/https://doi.org/10.1592/phco.27.11.1483 562 European Medicines Agency (EMA). (2023). Authorised COVID-19 vaccines. 563 564 https://www.ema.europa.eu/en/human-regulatory/overview/public-health-565 threats/coronavirus-disease-covid-19/treatments-vaccines/vaccines-covid-566 19/covid-19-vaccines-authorised#authorised-covid-19-vaccines-section 567 (Accessed 26 February 2023) Gesundheitsberichterstattung des Bundes. (2021). Gesundheitspersonal in 1.000. 568 569 Gliederungsmerkmale: Jahre, Deutschland, Alter, Beschäftigungsart, Beruf. 570 https://www.gbebund.de/gbe/lpkg olap tables.prc set orientation?p uid=gast&p aid=256329 571 572 89&p sprache=D&p help=2&p indnr=96&p ansnr=82673282&p version=2& D.000=1&D.002=1&D.767=1&D.489=2 (Accessed 26 February 2023) 573 574 Gholami, A., Jahromi, L. M., Zarei, E., & Dehghan, A. (2013). Application of WHOQOL-BREF in Measuring Quality of Life in Health-Care Staff. 575 576 International journal of preventive medicine, 4(7), 809-817. 577 https://pubmed.ncbi.nlm.nih.gov/24049600 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3775221/ 578 Gross, J. V., Mohren, J., & Erren, T. C. (2021). COVID-19 and healthcare workers: a 579 580 rapid systematic review into risks and preventive measures. BMJ Open, 11(1), 581 e042270-e042270. https://doi.org/10.1136/bmjopen-2020-042270 582 Harris, P. A., Taylor, R., Minor, B. L., Elliott, V., Fernandez, M., O'Neal, L., McLeod, 583 L., Delacqua, G., Delacqua, F., Kirby, J., & Duda, S. N. (2019). The REDCap 584 consortium: Building an international community of software platform partners. Journal of Biomedical Informatics, 95, 103208. 585 586 https://doi.org/https://doi.org/10.1016/j.jbi.2019.103208 Harris, P. A., Taylor, R., Thielke, R., Payne, J., Gonzalez, N., & Conde, J. G. (2009). 587 Research electronic data capture (REDCap)—A metadata-driven methodology 588 589 and workflow process for providing translational research informatics support. 590 Journal of Biomedical Informatics, 42(2), 377-381. https://doi.org/https://doi.org/10.1016/j.jbj.2008.08.010 591 592 Kow, C. S., & Hasan, S. S. (2021). Do sleep quality and sleep duration before or after COVID-19 vaccination affect antibody response? Chronobiology International, 593 594 38(7), 941-943. https://doi.org/10.1080/07420528.2021.1900216 595 Krone, M., Gütling, J., Wagener, J., Lâm, T.-T., Schoen, C., Vogel, U., Stich, A., 596 Wedekink, F., Wischhusen, J., Kerkau, T., Beyersdorf, N., Klingler, S., Backes,

597	S., Dölken, L., Gasteiger, G., Kurzai, O., Schubert-Unkmeir, A., & Tang, YW.
598	(2021). Performance of Three SARS-CoV-2 Immunoassays, Three Rapid
599	Lateral Flow Tests, and a Novel Bead-Based Affinity Surrogate Test for the
600	Detection of SARS-CoV-2 Antibodies in Human Serum. Journal of Clinical
601	Microbiology, 59(8), e00319-00321. https://doi.org/doi:10.1128/JCM.00319-21
602	Lammers-van der Holst, H. M., Lammers, G. J., van der Horst, G. T. J., Chaves, I.,
603	de Vries, R. D., GeurtsvanKessel, C. H., Koch, B., & van der Kuy, H. M.
604	(2022). Understanding the association between sleep, shift work and COVID-
605	19 vaccine immune response efficacy: Protocol of the S-CORE study. <i>Journal</i>
606	of Sleep Research, 31(2), e13496.
607	https://doi.org/https://doi.org/10.1111/jsr.13496
608	Lange, T., Dimitrov, S., Bollinger, T., Diekelmann, S., & Born, J. (2011). Sleep after
609	Vaccination Boosts Immunological Memory. <i>The Journal of Immunology</i> ,
610	187(1), 283-290. https://doi.org/10.4049/jimmunol.1100015
611	Lange, T., Perras, B., Fehm, H. L., & Born, J. (2003). Sleep enhances the human
612	antibody response to hepatitis A vaccination. <i>Psychosom Med</i> , 65(5), 831-
	835. https://doi.org/10.1097/01.psy.0000091382.61178.f1
613	
614 615	Mazereel, V., Van Assche, K., Detraux, J., & De Hert, M. (2021). COVID-19 vaccination for people with severe mental illness: why, what, and how? <i>The</i>
616	Lancet Psychiatry, 8(5), 444-450. https://doi.org/10.1016/S2215-
617	0366(20)30564-2
618	Montgomery, C. M., Humphreys, S., McCulloch, C., Docherty, A. B., Sturdy, S., &
619	Pattison, N. (2021). Critical care work during COVID-19: a qualitative study of
620	staff experiences in the UK. <i>BMJ Open</i> , <i>11</i> (5), e048124.
620	https://doi.org/10.1136/bmjopen-2020-048124
622	Morin, C. M., Vézina-Im, LA., Ivers, H., Micoulaud-Franchi, JA., Philip, P., Lamy,
623	Monn, C. M., Vezina-III, EA., Wers, H., Micodiadd-Francin, JA., Filip, F., Earry, M., & Savard, J. (2021). Prevalent, incident, and persistent insomnia in a
624	population-based cohort tested before (2018) and during the first-wave of
625	COVID-19 pandemic (2020). <i>Sleep</i> , <i>45</i> (1).
626	https://doi.org/10.1093/sleep/zsab258
627	Perkmann, T., Perkmann-Nagele, N., Koller, T., Mucher, P., Radakovics, A.,
628	Marculescu, R., Wolzt, M., Wagner, O. F., Binder, C. J., Haslacher, H., &
629	Powell, E. A. (2021). Anti-Spike Protein Assays to Determine SARS-CoV-2
630	Antibody Levels: a Head-to-Head Comparison of Five Quantitative Assays.
631	Microbiology Spectrum, 9(1), e00247-00221.
632	https://doi.org/doi:10.1128/Spectrum.00247-21
633	Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S.,
634	Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson,
635	K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck,
636	R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D.
637	B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
638	(2020). Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. New
639	England Journal of Medicine, 383(27), 2603-2615.
640	https://doi.org/10.1056/NEJMoa2034577
641	Prather, A. A., Hall, M., Fury, J. M., Ross, D. C., Muldoon, M. F., Cohen, S., &
642	Marsland, A. L. (2012). Sleep and Antibody Response to Hepatitis B
643	Vaccination. Sleep, 35(8), 1063-1069. https://doi.org/10.5665/sleep.1990
644	Prather, A. A., Pressman, S. D., Miller, G. E., & Cohen, S. (2021). Temporal Links
645	Between Self-Reported Sleep and Antibody Responses to the Influenza
646	Vaccine. International Journal of Behavioral Medicine, 28(1), 151-158.
647	https://doi.org/10.1007/s12529-020-09879-4


648 649 650 651 652	Rayatdoost, E., Rahmanian, M., Sanie, M. S., Rahmanian, J., Matin, S., Kalani, N., Kenarkoohi, A., Falahi, S., & Abdoli, A. (2022). Sufficient Sleep, Time of Vaccination, and Vaccine Efficacy: A Systematic Review of the Current Evidence and a Proposal for COVID-19 Vaccination. Yale J Biol Med, 95(2), 221-235.
653 654 655 656 657	 Reusch, J., Wagenhäuser, I., Gabel, A., Eggestein, A., Höhn, A., Lâm, T. T., Frey, A., Schubert-Unkmeir, A., Dölken, L., Frantz, S., Kurzai, O., Vogel, U., Krone, M., & Petri, N. (2022). Influencing factors of anti-SARS-CoV-2-spike-IgG antibody titers in healthcare workers: A cross-section study. <i>J Med Virol</i>, e28300. https://doi.org/10.1002/jmv.28300
658 659	Riemann, D., Krone, L. B., Wulff, K., & Nissen, C. (2020). Sleep, insomnia, and depression. <i>Neuropsychopharmacology</i> , <i>45</i> (1), 74-89.
660 661	https://doi.org/10.1038/s41386-019-0411-y Riemann, D., Spiegelhalder, K., Feige, B., Voderholzer, U., Berger, M., Perlis, M., &
662 663	Nissen, C. (2010). The hyperarousal model of insomnia: A review of the concept and its evidence. <i>Sleep Medicine Reviews</i> , <i>14</i> (1), 19-31.
664	https://doi.org/https://doi.org/10.1016/j.smrv.2009.04.002
665 666	Robert Koch-Institut (RKI). (2021). Epidemiologisches Bulletin: 14. Aktualisierung der COVID-19-Impfempfehlung.
667 668	https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2021/Ausgaben/48_21.pd f? blob=publicationFile (Accessed 26 February 2023)
669	Skevington, S. M. (1999). Measuring quality of life in britain: Introducing the
670	WHOQOL-100. Journal of Psychosomatic Research, 47(5), 449-459.
671	https://doi.org/https://doi.org/10.1016/S0022-3999(99)00051-3
672	Soldatos, C. R., Dikeos, D. G., & Paparrigopoulos, T. J. (2000). Athens Insomnia
673	Scale: validation of an instrument based on ICD-10 criteria. J Psychosom Res,
674	48(6), 555-560. https://doi.org/10.1016/s0022-3999(00)00095-7
675	Spiegel, K., Sheridan, J. F., & Van Cauter, E. (2002). Effect of sleep deprivation on
676	response to immunization. <i>JAMA</i> , 288(12), 1471-1472.
677	https://doi.org/10.1001/jama.288.12.1471-a
678 670	Taylor, D. J., Kelly, K., Kohut, M. L., & Song, KS. (2017). Is Insomnia a Risk Factor
679 680	for Decreased Influenza Vaccine Response? <i>Behavioral Sleep Medicine</i> ,
680 681	<i>15</i> (4), 270-287. https://doi.org/10.1080/15402002.2015.1126596 van den Berg, T. I. J., Elders, L. A. M., de Zwart, B. C. H., & Burdorf, A. (2009). The
682	effects of work-related and individual factors on the Work Ability Index: a
683	systematic review. Occupational and Environmental Medicine, 66(4), 211.
684	https://doi.org/10.1136/oem.2008.039883
685	Wolkow, A., Ferguson, S., Aisbett, B., & Main, L. (2015). Effects of work-related sleep
686	restriction on acute physiological and psychological stress responses and their
687	interactions: A review among emergency service personnel. Int J Occup Med
688	<i>Environ Health</i> , <i>28</i> (2), 183-208. https://doi.org/10.13075/ijomeh.1896.00227
689	Wu, F., Zhao, S., Yu, B., Chen, YM., Wang, W., Song, ZG., Hu, Y., Tao, ZW.,
690	Tian, JH., Pei, YY., Yuan, ML., Zhang, YL., Dai, FH., Liu, Y., Wang, Q
691	M., Zheng, JJ., Xu, L., Holmes, E. C., & Zhang, YZ. (2020). A new
692	coronavirus associated with human respiratory disease in China. <i>Nature</i> ,
693 694	<i>579</i> (7798), 265-269. https://doi.org/10.1038/s41586-020-2008-3 Xiao, K., Gillissie, E. S., Lui, L. M. W., Ceban, F., Teopiz, K. M., Gill, H., Cao, B., Ho,
695	R., Rosenblat, J. D., & McIntyre, R. S. (2022). Immune response to
695 696	vaccination in adults with mental disorders: A systematic review. <i>Journal of</i>
697	Affective Disorders, 304, 66-77.
698	https://doi.org/https://doi.org/10.1016/j.jad.2022.02.025
	······································


- Zhu, J., Zhang, M., Sanford, L. D., & Tang, X. (2021). Advice for COVID-19
 vaccination: get some sleep. *Sleep and Breathing*, 25(4), 2287-2288.
- 701 https://doi.org/10.1007/s11325-021-02313-3
- Zimmermann, P., & Curtis, N. (2019). Factors That Influence the Immune Response
 to Vaccination. *Clinical Microbiology Reviews*, *32*(2), e00084-00018.
- 704 https://doi.org/doi:10.1128/CMR.00084-18
- 705






B








14-days post-vaccination n=1,082

3-month follow-up



Anti-SARS-CoV-2-Spike IgG [BAU/ml]





14-days post-vaccination n=154

